Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey.

Autor:	Balcı U; Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, TUR., Üser Ü; Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, TUR., Tahmaz A; Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, TUR., Sarigul Yildirim F; Infectious Diseases and Clinical Microbiology, Akdeniz Sağlık Vakfı Yaşam Hospital, Antalya, TUR.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Oct 18; Vol. 15 (10), pp. e47253. Date of Electronic Publication: 2023 Oct 18 (Print Publication: 2023).
DOI:	10.7759/cureus.47253
Abstrakt:	Introduction: Single-tablet regimens (STRs) can increase treatment success and even improve the quality of life of human immunodeficiency virus (HIV) patients. In this study, we aim to analyze the real-life efficacy and tolerability data of people living with HIV (PLWH) initiated on or switched to bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) as first-line treatment. Materials and Methods: This retrospective analysis was performed in HIV-1-positive patients who were initiated BIC/FTC/TAF in the HIV clinic between June 2020 and June 2022. Patients who received BIC/FTC/TAF for at least 12 months were included in this study. Virological suppression, laboratory parameters, side effects, and immunological response were analyzed at one, three, six, nine, and 12 months. Results: A total of 116 patients, 66 (56.9%) treatment-experienced and 50 (43.1%) naive, were evaluated within the scope of the study. In the naive patient group, baseline HIV-RNA, CD4+ and CD8+ T cell counts, CD4/CD8 ratio, and estimated glomerular filtration rate (eGFR) values were significantly different in different follow-up months. The number of patients with HIV-1 RNA levels below 50 copies/mL was 55.9% in the first month, 73.7% in the third month, 90.2% in the sixth month, and 100% in the ninth and 12th months. Conclusion: In our real-life observational study, BIC/FTC/TAF treatment achieved rapid viral suppression, maintained viral suppression in virally suppressed patients, and was effective for immunological recovery in both treatment-experienced and naive HIV patients. No serious side effects were observed. Our study has proved the potential of BIC/FTC/TAF as an important option in the treatment of HIV patients. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Balcı et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu